Impairment of transendothelial leukocyte migration by iron complexes

Journal of the American Society of Nephrology

Volumn 14, Issue 10, 2003, Pages 2639-2644

  Sengoelge, Gürkan ^a,b   Kletzmayr, Josef ^a   Ferrara, Ilse ^a   Perschl, Agnes ^a   Hörl, Walter H ^a   Sunder Plassmann, Gere ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Division of Nephrology and Dialysis   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC GLUCONATE; FERROUS GLUCONATE; IRON COMPLEX; IRON SACCHARATE;

ARTICLE; CARDIOVASCULAR DISEASE; CELL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INFECTION; KIDNEY ISCHEMIA; LEUKOCYTE MIGRATION INHIBITION; PRIORITY JOURNAL;

EID: 0141455273     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000087087.61306.4A     Document Type: Article

References (45)

1. Sunder-Plassmann G, Hörl WH: Erythropoietin and iron. Clin Nephrol 47: 141-57, 1997
2. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure: European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 14[Suppl 5]: 1-50, 1999
3. NKF DOQI Work group: IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 37 [Suppl 1]: S182-S238, 2001
4. Fishbane S, Kowalski EA: The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 13: 381-384, 2000
5. Rooyakkers TM, Stroes ES, Kooistra MP, van Faassen EE, Hider RC, Rabelink TJ, Marx JJ: Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32[Suppl 1]: 9-16, 2002
6. Sunder-Plassmann G, Hörl WH: Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Safety 17: 241-250, 1997
7. Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40: 90-103, 2002
8. Patruta SI, Hörl WH: Iron and infection. Kidney Int 55[Suppl 69]: S125-S130, 1999
9. Sunder-Plassmann G, Patruta SI, Hörl WH: Pathobiology of the role of iron in infection. Am J Kidney Dis 34 [Suppl 2]: S25-S29, 1999
10. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 15: 1827-1834, 2000
11. Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52: 2745-2756, 1973
12. Metcalf JA, Gallin JI, Nauseef WM, Root RK: Laboratory Manual of Neutrophil Function, New York, Raven Press, 1986, pp 3-17
13. Sunder-Plassmann G, Hofbauer R, Sengoelge G, Hörl WH: Quantification of leukocyte migration: Improvement of a method. Immunol Invest 25: 49-63, 1996
14. Sengoelge G, Födinger M, Skoupy S, Ferrara I, Zangerle C, Rogy M, Hörl WH, Sunder-Plassmann G, Menzel J: Endothelial cell adhesion molecule and PMNL response to inflammatory stimuli and AGE-modified fibronectin. Kidney Int 54: 1637-1651, 1998
15. Yee J, Besarab A: Iron sucrose: The oldest iron therapy becomes new. Am J Kidney Dis 40: 1111-1121, 2002
16. Fishbane S, Wagner J: Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. Am J Kidney Dis 37: 879-883, 2001
17. Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB: Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 37: 300-307, 2001
18. Chandler G, Harchowal J, Macdougall IC: Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 38: 988-991, 2001
19. Richardson D, Bartlett C, Will EJ: Optimizing erythropoietin therapy in hemodialysis patients. Am J Kidney Dis 38: 109-117, 2001
20. Van Wyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, Levin N: Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 36: 88-97, 2000
21. Coyne DW, Adkinson NF, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, Michael B, Folkert V, Batlle D, Trout JR, Dahl N, Myirski P, Strobos J, Warnock DG: Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 63: 217-224, 2003
22. Michael B, Coyne DW, Fishbane S, Folkert V, Lynn R, Nissenson AR, Agarwal R, Eschbach JW, Fadem SZ, Trout JR, Strobos J, Warnock DG: Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 61: 1830-1839, 2002
23. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J: Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis 33: 471-482, 1999
24. Sunder-Plassmann G, Hörl WH: Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 11: 1797-1802, 1996
25. Folkert VW, Michael B, Agarwal R, Coyne DW, Dahl N, Myirski P, Warnock DG: Chronic use of sodium ferric gluconate complex in hemodialysis patients: Safety of higher-dose (> or =250 mg) administration. Am J Kidney Dis 41: 651-657, 2003
26. Zhou XJ, Laszik Z, Wang XQ, Silva FG, Vaziri ND: Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest 80: 1905-1914, 2000
27. Tampo Y, Kotamraju S, Chitambar CR, Kalivendi SV, Keszler A, Joseph J, Kalyanaraman B: Oxidative stress-induced iron signaling is responsible for peroxide-dependent oxidation of dichlorodihydrofluorescein in endothelial cells: Role of transferrin receptor-dependent iron uptake in apoptosis. Circ Res 92: 56-63, 2003
28. Banyai S, Rainer V, Derfler K, Druml W, Hörl WH, Sunder-Plassmann G: Bleomycin detectable free iron (BDI) is present in patients on intravenous (IV) iron therapy [Abstract]. J Am Soc Nephrol 9: 198A, 1998
29. Kooistra MP, Kersting S, Gosriwatana I, Lu S, Nijhoff-Schutte J, Hider RC, Marx JJ: Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 32[Suppl 1]: 36-41, 2002
30. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11: 539-549, 2000
31. Gaenzer H, Marschang P, Sturm W, Neumayr GG, Vogel W, Patsch J, Weiss GG: Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol 40: 2189-2194, 2002
32. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF Jr, Vita JA: Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 103: 2799-2804, 2001
33. Shah SV, Alam MG: Role of iron in atherosclerosis. Am J Kidney Dis 41: S80-S83, 2003
34. Sullivan JL: Iron therapy and cardiovascular disease. Kidney Int 55[Suppl 69]: S135-S137, 1999
35. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intimamedia thickness in end-stage renal disease. Circulation 106: 2212-2217, 2002
36. Patruta SI, Edlinger R, Sunder-Plassmann G, Hòrl WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9: 655-663, 1998
37. Gartside PS, Glueck CJ: The important role of modifiable dietary and behavioral characteristics in the causation and prevention of coronary heart disease hospitalization and mortality: The prospective NHANES I follow-up study. J Am Coll Nutr 14: 71-79, 1995
38. Corti MC, Guralnik JM, Salive ME, Ferrucci L, Pahor M, Wallace RB, Hennekens CH: Serum iron level, coronary artery disease, and all-cause mortality in older men and women. Am J Cardiol 79: 120-127, 1997
39. Miller M, Hutchins GM: Hemochromatosis, multiorgan hemosiderosis, and coronary artery disease. JAMA 272: 231-233, 1994
40. Guo D, Jaber BL, Lee S, Perianayagam MC, King AJ, Pereira BJ, Balakrishnan VS: Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol 58: 134-142, 2002
41. Hoen B, Paul-Dauphin A, Kessler M: Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 57: 457-461, 2002
42. Hoen B, Paul-Dauphin A, Hestin D, Kessler M: EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9: 869-876, 1998
43. de Silva A, Atukorala S, Weerasinghe I, Ahluwalia N: Iron supplementation improves iron status and reduces morbidity in children with or without upper respiratory tract infections: A randomized controlled study in Colombo, Sri Lanka. Am J Clin Nutr 77: 234-241, 2003
44. Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM: A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 16: 1239-1244, 2001
45. Matzner Y, Goldfarb A, Abrahamov A, Drexler R, Friedberg A, Rachmilewitz EA: Impaired neutrophil chemotaxis in patients with thalassaemia major. Br J Haematol 85: 153-158, 1993